Search
Fexinidazole
go.drugbank.com/drugs/DB12265Approved[A237555, A237560] Fexinidazole received a positive opinion from the European Medicines Agency (EMA) in November 2018 and was approved by the FDA on July 16, 2021. … all-oral treatment for first and second stage HAT caused by _T. brucei gambiense_.
Categories: Agents Against Leishmaniasis and Trypanosomiasis, Antiparasitic Products, Insecticides and RepellentsFidanacogene elaparvovec
go.drugbank.com/drugs/DB16783ApprovedInvestigationalfrom week 12 to month 15 compared to an ABR of 4.43 for the pre-treatment period. … soft tissues or joints, and severe subcutaneous hematomas.
Categories: Blood and Blood Forming OrgansSerdexmethylphenidate
go.drugbank.com/drugs/DB16629Approved[A230698, A230703] The underlying cause of ADHD is unclear but likely involves dysfunction in dopaminergic and noradrenergic neurotransmission, as evidenced by the clear beneficial effect of CNS stimulants … Attention Deficit Hyperactivity Disorder (ADHD) is an early-onset neurodevelopmental disorder that often extends into adulthood and is characterized by developmentally inappropriate and impaired attention
Categories: dexmethylphenidate and serdexmethylphenidate, Psychostimulants, Agents Used for ADHD and NootropicsEprosartan
go.drugbank.com/drugs/DB00876ApprovedInvestigationalBy preventing the binding of angiotensin II to AT1, vascular smooth muscle relaxes and vasodilation occurs. By inhibiting norepinephrine production, blood pressure is further reduced. … Eprosartan is an angiotensin II receptor antagonist used to treat hypertension. It performs 2 actions on the renin angiotensin system.
Synonyms: (E)-3-[2-n-butyl-1-{(4-carboxyphenyl)methyl}-1H-imidazol-5-yl]-2-(2-thienyl)methyl-2-propenoic acidCategories: eprosartan and diuretics, Angiotensin II receptor blockers (ARBs) and diureticsBacillus calmette-guerin substrain russian BCG-I live antigen
go.drugbank.com/drugs/DB16648ApprovedInvestigationalthought to work by stimulating a local immune and inflammatory response in the bladder. … It was developed to alleviate Canada's multi-year shortage of BCG vaccine, and is expected to be available by mid-2021.[L32734]
Ethinamate
go.drugbank.com/drugs/DB01031ApprovedIllicitWithdrawnStructurally, it does not resemble the barbituates, but it shares many effects with this class of drugs; the depressant effects of ethinamate are, however, generally milder than those of most barbiturates … Nevertheless, the medication itself is generally no longer effective after using it for greater than 7 days.
Onasemnogene abeparvovec
go.drugbank.com/drugs/DB15528ApprovedInvestigational[L9194] Onasemnogene abeparvovec for therapeutic use and marketing is currently being assessed by the EU and an intrathecal formulation of the drug is currently undergoing clinical development in the USA … [A187250] As there is no cure for SMA, onasemnogene abeparvovec is a disease-modifying agent that decelerates the disease progression, improves motor function, and manages the symptoms.
Categories: Cellular and Gene Therapy, Amino Acids, Peptides, and ProteinsEnflurane
go.drugbank.com/drugs/DB00228ApprovedVet approvedWithdrawn[L13646,L13649] Unlike its other inhalational anesthetic counterparts including [isoflurane] and [halothane], enflurane is known to induce seizure activity. … Enflurane is a halogenated inhalational anesthetic initially approved by the FDA in 1972. Since this date, it has been withdrawn from the US market.
Clesrovimab
go.drugbank.com/drugs/DB18877ApprovedInvestigational[L53233] As there are no RSV vaccines approved for infant patients, nor are vaccines immediately effective in this population, clesrovimab and similar monoclonal antibodies like [nirsevimab] are designed … to provide passive immunization against RSV infection as an alternative means of protection.
Categories: Amino Acids, Peptides, and ProteinsCertolizumab pegol
go.drugbank.com/drugs/DB08904ApprovedInvestigational[A176606] It was developed and manufactured by UCB Pharma, first FDA approved in 2008[L45018] and updated for a new indication on March 28, 2019.[L5819] … The absence of the Fc region was ideated to prevent complement fixation and antibody-mediated cytotoxicity as well as to markedly increase its half-life.
Categories: Amino Acids, Peptides, and Proteins, Antineoplastic and Immunomodulating Agents